Clinical Trial Update: Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant chemoradiotherapy followed by sequential ipilimumab and nivolumab in rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Johannes Laengle, MD, PhD | Conditions: Rectal Cancer | Phase 2 | Status: COMPLETED